• Citer

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

par Dixon, Bradley Patton;Kavanagh, David D.H.;Aris, Alvaro Domingo Madrid;Adams, Brigitte ;Kang, Hee Gyung;Wang, Edward;Garlo, Katherine;Ogawa, Masayo;Amancha, Praveen;Chakravarty, Sourish;Heyne, Nils;Kim, Seong Heon;Cataland, Spero;Yoon, Sung Soo;Miyakawa, Yoshitaka;Luque, Yosu;Muff-Luett, Melissa;Tanaka, Kazuki;Greenbaum, Larry L.A.
Référence Kidney Medicine, 6, 8, 100855
Publication Publié, 2024-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials
Auteur:	Dixon, Bradley Patton; Kavanagh, David D.H.; Aris, Alvaro Domingo Madrid; Adams, Brigitte; Kang, Hee Gyung; Wang, Edward; Garlo, Katherine; Ogawa, Masayo; Amancha, Praveen; Chakravarty, Sourish; Heyne, Nils; Kim, Seong Heon; Cataland, Spero; Yoon, Sung Soo; Miyakawa, Yoshitaka; Luque, Yosu; Muff-Luett, Melissa; Tanaka, Kazuki; Greenbaum, Larry L.A.
Informations sur la publication:	Kidney Medicine, 6, 8, 100855
Statut de publication:	Publié, 2024-08
Sujet CREF:	Généralités
Mots-clés:	Adult
	atypical hemolytic uremic syndrome
	complement C5 inhibitor
	efficacy
	hematology
	nephrology
	pediatric
	ravulizumab
	safety
	thrombotic microangiopathy
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2590-0595
	info:doi/10.1016/j.xkme.2024.100855
	info:pii/S2590059524000669
	info:scp/85198062971